Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

Clinical Pharmacology and Therapeutics
C S YuanJ Moss

Abstract

Methylnaltrexone is a quaternary opioid antagonist with limited ability to cross the blood-brain barrier and the potential to antagonize the peripherally mediated effects of opioids. The effectiveness of methylnaltrexone in preventing morphine-induced changes in gastrointestinal motility and transit without affecting analgesia was evaluated in humans. Twelve healthy volunteers were given intravenous placebo, placebo plus 0.05 mg/kg morphine, or 0.45 mg/kg methylnaltrexone plus 0.05 mg/kg morphine. Oral-cecal transit time was assessed by the pulmonary hydrogen measurement technique, and analgesia was measured with use of the cold-pressor test. Morphine significantly increased oral-cecal transit time from 104.6 +/- 31.1 minutes (mean +/- SD) to 163.3 +/- 39.8 minutes (p < 0.01). Methylnaltrexone prevented 97% of morphine-induced increase in oral-cecal transit time (106.3 +/- 39.8 minutes; not significant compared with baseline; p < 0.01 compared with morphine alone). Methylnaltrexone did not affect the analgesic effect of morphine on both pain intensity and pain bothersomeness ratings. At a higher dose of morphine (0.1 mg/kg), our preliminary results indicated that 0.45 mg/kg methylnaltrexone also prevented the morphine-induced d...Continue Reading

References

Apr 1, 1977·The American Journal of Digestive Diseases·J H Bond, M D Levitt
Aug 1, 1992·Journal of Pain and Symptom Management·P Glare, J N Lickiss
Jul 1, 1992·Clinical Pharmacology and Therapeutics·J A Culpepper-MorganM J Kreek
Oct 1, 1989·Nursing·M McCaffrey, A Beebe
Nov 1, 1989·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A N KotakeL I Goldberg
Mar 1, 1985·Neuropharmacology·D R Brown, L I Goldberg
Mar 1, 1987·The Medical Clinics of North America·R K Portenoy
Mar 1, 1988·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·J D GowanJ Kitts
Aug 1, 1987·Digestive Diseases and Sciences·G BasiliscoP A Bianchi
Jan 1, 1985·Annual Review of Pharmacology and Toxicology·L Manara, A Bianchetti
Mar 1, 1966·Clinical Pharmacology and Therapeutics·B B WolffE Laska
Jan 1, 1984·Pain·T D Walsh
Jul 1, 1983·Annals of Emergency Medicine·K A HandalF R Salamone
Mar 12, 1982·European Journal of Pharmacology·J RussellH Merz
Apr 1, 1981·Regulatory Peptides·P Melchiorri, L Negri
Mar 1, 1995·Anesthesia and Analgesia·J P ZacnyJ L Apfelbaum
Aug 1, 1993·Journal of Clinical Pharmacology·J F FossL I Goldberg

❮ Previous
Next ❯

Citations

Sep 29, 2001·The New England Journal of Medicine·A TaguchiA Kurz
May 30, 2008·The New England Journal of Medicine·Jay ThomasRobert J Israel
Feb 12, 2002·Pharmacotherapy·Christopher M HerndonPamala A Hallin
Jan 1, 2008·Clinical and Experimental Gastroenterology·Beverley Greenwood-Van Meerveld, Kelly M Standifer
Jan 1, 2009·Journal of Pain Research·Joanne Droney, Julia Riley
Mar 18, 2010·Therapeutics and Clinical Risk Management·Katri Elina Clemens, Eberhard Klaschik
Mar 17, 2012·Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association·Sanjay MarwahPradeep Tinna
Aug 13, 2011·Clinical Medicine Insights. Oncology·S BaderG Becker
Jan 5, 2014·BMC Gastroenterology·Inna Rozov-UngMichael D Sitrin
Oct 16, 2003·The Journal of Pharmacology and Experimental Therapeutics·Wen-Zhe HoJonathan Moss
Jan 31, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Laura AnselmiCatia Sternini
Jun 11, 2015·Scandinavian Journal of Gastroenterology·Bishal GyawaliYuichi Ando
Aug 5, 2009·Expert Opinion on Emerging Drugs·Michael D CrowellJohn K Dibaise
Oct 2, 2008·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Ewan McNicolDaniel Carr
Jan 25, 2007·Expert Opinion on Investigational Drugs·Peter Holzer
Apr 26, 2006·Expert Opinion on Investigational Drugs·Chun-Su Yuan, Robert J Israel
May 11, 2005·Expert Opinion on Investigational Drugs·Paul Neary, Conor P Delaney
Dec 26, 2012·Expert Review of Gastroenterology & Hepatology·Sabine BaderGerhild Becker
Apr 15, 2009·Expert Opinion on Pharmacotherapy·Rebecca R Cannom, Rodney J Mason
Oct 13, 2009·Expert Review of Gastroenterology & Hepatology·Laura DiegoCharles F von Gunten
Mar 27, 2004·Life Sciences·Han H AungChun-Su Yuan
Jan 18, 2006·Current Problems in Surgery·Benjamin Person, Steven D Wexner
Jul 3, 2015·Therapeutic Advances in Gastroenterology·Alfred D Nelson, Michael Camilleri
Mar 16, 2016·Therapeutic Advances in Chronic Disease·Alfred D Nelson, Michael Camilleri
Jan 6, 2004·Medicinal Research Reviews·Masakatsu Eguchi
Feb 7, 2018·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·H HalawiM Camilleri
Apr 23, 2015·International Journal of Palliative Nursing·Gina Santucci, Vanessa Battista
Feb 24, 2011·The American Journal of Gastroenterology·Michael Camilleri
Aug 13, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·H U De SchepperM Camilleri
Jul 7, 2018·Expert Opinion on Pharmacotherapy·Shilan MozaffariMohammad Abdollahi
Oct 22, 2004·Journal of Clinical Pharmacology·Chun-Su YuanYukihiro Shoyama
Nov 24, 1998·Journal of Clinical Pharmacology·C S YuanJ Moss
Aug 7, 2002·Journal of Clinical Pharmacology·Chun-Su YuanXiongfe Guan
Jan 1, 1997·British Journal of Clinical Pharmacology·C H Wilder-Smith, A Bettiga
Feb 29, 2008·World Journal of Surgery·Avo ArtinyanRobert W Beart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.